Participants
psychiatric, COPD, heart insufficiency
NEUROLOGICAL DISEASE, HEART INSUFFICIENCY, COPD, CHRONIC OBSTRUCTIVE LUNG DISEASE, HEART
Control participants were recruited from December 2021 until March 2022 to take part in this prospective study. Informed consent was obtained from each participant prior to inclusion in the study. The participants were included if they were ≥ 18 years old. Exclusion criteria for participants included (1) history of neurological disease, (2) psychiatric or medical morbidity interfering with the experimental tasks, (3) orthopedic conditions, (4) heart insufficiency NYHA III–IV (New York Heart Association; heart insufficiency symptoms after light endurance, III, and permanent symptoms, IV), (5) COPD Gold III or IV (Global Initiative for Chronic Obstructive Lung Disease), and (6) dermatological concerns interfering with proper attachment of electrodes and sensors to the skin. The sample size was based on previous studies investigating test–retest reliability and agreement of coherence in control participants (Gennaro and de Bruin 